Описание
Summary of clinical trial data evaluating curcumin formulations in neurological conditions such as Alzheimer's disease and cognitive decline. Results have been mixed, reflecting the complexity of translating preclinical findings.
Cite This Figure
![Figure 3: Summary of clinical trial data evaluating curcumin formulations in neurological conditions such as Alzheimer's disease and cognitive decline. Results have been mixed, reflecting the complexity of translating preclinical findings.]() > Source: Stella Gagliardi et al. "Curcumin Formulations and Trials: What's New in Neurological Diseases.." *Molecules (Basel, Switzerland)*, 2020. PMID: [33217959](https://pubmed.ncbi.nlm.nih.gov/33217959/)
<figure> <img src="" alt="Summary of clinical trial data evaluating curcumin formulations in neurological conditions such as Alzheimer's disease and cognitive decline. Results have been mixed, reflecting the complexity of translating preclinical findings." /> <figcaption>Figure 3. Summary of clinical trial data evaluating curcumin formulations in neurological conditions such as Alzheimer's disease and cognitive decline. Results have been mixed, reflecting the complexity of translating preclinical findings.<br> Source: Stella Gagliardi et al. "Curcumin Formulations and Trials: What's New in Neurological Diseases.." <em>Molecules (Basel, Switzerland)</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33217959/">33217959</a></figcaption> </figure>